Literature DB >> 33919123

Mesenchymal Stromal Cell Therapy in Novel Porcine Model of Diffuse Liver Damage Induced by Repeated Biliary Obstruction.

Lucie Vištejnová1,2, Václav Liška1,3, Arvind Kumar1,3, Jana Křečková1, Ondřej Vyčítal1,3, Jan Brůha1,3, Jan Beneš1,4, Yaroslav Kolinko1,2, Tereza Blassová1,2, Zbyněk Tonar1,2, Michaela Brychtová1, Marie Karlíková1, Jaroslav Racek5, Hynek Mírka1,6, Petr Hošek1, Daniel Lysák1, Milena Králíčková1,2.   

Abstract

In liver surgery, biliary obstruction can lead to secondary biliary cirrhosis, a life-threatening disease with liver transplantation as the only curative treatment option. Mesenchymal stromal cells (MSC) have been shown to improve liver function in both acute and chronic liver disease models. This study evaluated the effect of allogenic MSC transplantation in a large animal model of repeated biliary obstruction followed by partial hepatectomy. MSC transplantation supported the growth of regenerated liver tissue after 14 days (MSC group, n = 10: from 1087 ± 108 (0 h) to 1243 ± 92 mL (14 days); control group, n = 11: from 1080 ± 95 (0 h) to 1100 ± 105 mL (14 days), p = 0.016), with a lower volume fraction of hepatocytes in regenerated liver tissue compared to resected liver tissue (59.5 ± 10.2% vs. 70.2 ± 5.6%, p < 0.05). Volume fraction of connective tissue, blood vessels and bile vessels in regenerated liver tissue, serum levels of liver enzymes (AST, ALT, ALP and GGT) and liver metabolites (albumin, bilirubin, urea and creatinine), as well as plasma levels of IL-6, IL-8, TNF-α and TGF-β, were not affected by MSC transplantation. In our novel, large animal (pig) model of repeated biliary obstruction followed by partial hepatectomy, MSC transplantation promoted growth of liver tissue without any effect on liver function. This study underscores the importance of translating results between small and large animal models as well as the careful translation of results from animal model into human medicine.

Entities:  

Keywords:  hepatectomy; mesenchymal stromal cell; pig model; quantitative histology; secondary biliary cirrhosis

Mesh:

Year:  2021        PMID: 33919123     DOI: 10.3390/ijms22094304

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  46 in total

1.  Distribution of Connective Tissue in the Male and Female Porcine Liver: Histological Mapping and Recommendations for Sampling.

Authors:  P Mik; Z Tonar; A Malečková; L Eberlová; V Liška; R Pálek; J Rosendorf; M Jiřík; H Mírka; M Králíčková; K Witter
Journal:  J Comp Pathol       Date:  2018-06-28       Impact factor: 1.311

2.  Factors predicting failure following high bilio-enteric anastomosis for post-cholecystectomy benign biliary strictures.

Authors:  Biju Pottakkat; Ranjit Vijayahari; Anand Prakash; Rajaneesh Kumar Singh; Anu Behari; Ashok Kumar; Vinay K Kapoor; Rajan Saxena
Journal:  J Gastrointest Surg       Date:  2010-06-30       Impact factor: 3.452

3.  The bone marrow functionally contributes to liver fibrosis.

Authors:  Francesco P Russo; Malcolm R Alison; Brian W Bigger; Eunice Amofah; Aikaterini Florou; Farhana Amin; George Bou-Gharios; Rosemary Jeffery; John P Iredale; Stuart J Forbes
Journal:  Gastroenterology       Date:  2006-05       Impact factor: 22.682

4.  The effects of cyclosporin A and Heteropterys tomentosa on the rat liver.

Authors:  Karine M de Freitas; Jacqueline M Almeida; Juliana C Monteiro; Maria Aparecida S Diamante; Jéssica S F do Vale; Camila Camargo; Marçal H A Jorge; Heidi Dolder
Journal:  An Acad Bras Cienc       Date:  2015-03       Impact factor: 1.753

5.  Orthotopic liver transplantation for cholestatic diseases.

Authors:  W Patkowski; M Skalski; K Zieniewicz; P Nyckowski; P Smoter; M Krawczyk
Journal:  Hepatogastroenterology       Date:  2010 May-Jun

Review 6.  Secondary sclerosing cholangitis.

Authors:  Petra Ruemmele; Ferdinand Hofstaedter; Cornelia M Gelbmann
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-05       Impact factor: 46.802

7.  Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis.

Authors:  Mehdi Mohamadnejad; Kamran Alimoghaddam; Mandana Mohyeddin-Bonab; Mohamad Bagheri; Maryam Bashtar; Hossein Ghanaati; Hossein Baharvand; Ardeshir Ghavamzadeh; Reza Malekzadeh
Journal:  Arch Iran Med       Date:  2007-10       Impact factor: 1.354

8.  Bone marrow multipotent mesenchymal stromal cells do not reduce fibrosis or improve function in a rat model of severe chronic liver injury.

Authors:  Adriana B Carvalho; Luiz Fernando Quintanilha; Juliana V Dias; Bruno D Paredes; Elida G Mannheimer; Felipe G Carvalho; Karina D Asensi; Bianca Gutfilen; Lea Mirian B Fonseca; Celia Maria C Resende; Guilherme F M Rezende; Christina M Takiya; Antonio Carlos Campos de Carvalho; Regina C S Goldenberg
Journal:  Stem Cells       Date:  2008-02-28       Impact factor: 6.277

9.  Immunomodulation By Therapeutic Mesenchymal Stromal Cells (MSC) Is Triggered Through Phagocytosis of MSC By Monocytic Cells.

Authors:  Samantha F H de Witte; Franka Luk; Jesus M Sierra Parraga; Madhu Gargesha; Ana Merino; Sander S Korevaar; Anusha S Shankar; Lisa O'Flynn; Steve J Elliman; Debashish Roy; Michiel G H Betjes; Philip N Newsome; Carla C Baan; Martin J Hoogduijn
Journal:  Stem Cells       Date:  2018-02-01       Impact factor: 6.277

10.  Effect of bone marrow-derived mesenchymal stem cells on hepatic fibrosis in a thioacetamide-induced cirrhotic rat model.

Authors:  Yoon Ok Jang; Moon Young Kim; Mee Yon Cho; Soon Koo Baik; Youn Zoo Cho; Sang Ok Kwon
Journal:  BMC Gastroenterol       Date:  2014-11-25       Impact factor: 3.067

View more
  1 in total

1.  Regenerative Medicine: Role of Stem Cells and Innovative Biomaterials 2.0.

Authors:  Marco Tatullo; Adriano Piattelli; Barbara Zavan
Journal:  Int J Mol Sci       Date:  2022-04-11       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.